Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2014
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2022 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. Cohen EEW, et al. Among authors: bagulho t. Clin Cancer Res. 2022 Mar 15;28(6):1157-1166. doi: 10.1158/1078-0432.CCR-21-1411. Clin Cancer Res. 2022. PMID: 34965944 Free PMC article. Clinical Trial.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Confavreux C, et al. Among authors: bagulho t. Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.